SCHEMBL5169220

SCHEMBL5169220

c1ccc(C2=NO2)cc1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23241303 0.67 SMN1; SMN2 (0.39)
Biphenyl SCHEMBL28890607 0.67 ALDH1A1 (1.00)
Biphenyl SCHEMBL1358618 0.67 ALDH1A1 (1.00)
SCHEMBL30108088 0.67 ALDH1A1 (1.00)
SCHEMBL29560186 0.67 ALDH1A1 (1.00)
Biphenyl SCHEMBL2548048 0.67 ALDH1A1 (1.00)
Biphenyl SCHEMBL4002609 0.67 ALDH1A1 (1.00)
Biphenyl SCHEMBL164 0.67 ALDH1A1 (1.00)
Biphenyl SCHEMBL29008551 0.67 ALDH1A1 (1.00)
SCHEMBL30629023 0.67 ALDH1A1 (1.00)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020052373-A1 Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease ZORN STEVIN H (US) 2002-05-02 US claimed
EP-1201268-A2 Combinations of D4 dopamine receptor antagonists with acetylcholine esterase inhibitors Pfizer Products Inc. (US) 2002-05-02 EP claimed
EP-1343752-B1 METHOD FOR PRODUCING N-SUBSTITUTED HYDROXYLAMINES AND THE SALTS THEREOF SALTIGO GMBH (DE) 2007-05-02 EP disclosed
EP-1343752-A2 METHOD FOR PRODUCING N-SUBSTITUTED HYDROXYLAMINES AND THE SALTS THEREOF Bayer Aktiengesellschaft (DE) 2003-09-17 EP disclosed
WO-2002048093-A2 METHOD FOR PRODUCING N-SUBSTITUTED HYDROXYLAMINES AND THE SALTS THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2002-06-20 WO disclosed
US-20020052373-A1 Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease ZORN STEVIN H (US) 2002-05-02 US disclosed
EP-1201268-A2 Combinations of D4 dopamine receptor antagonists with acetylcholine esterase inhibitors Pfizer Products Inc. (US) 2002-05-02 EP disclosed